Table 2.
The efficacy of the vaccination.
| Contrast | Challenge treatment | Challenge No. | Odds ratio | SE | p -value | PF |
|---|---|---|---|---|---|---|
| Site A – Graz Austria | ||||||
| AFB bacterin vs. Placebo | P. larvae | 1 | 0.56 | 0.14 | 0.02 | 0.303 |
| 2 | 0.57 | 0.14 | 0.02 | 0.275 | ||
| Control | 1 | 0.73 | 0.64 | 0.72 | - | |
| 2 | 0.48 | 0.25 | 0.16 | - | ||
| Site B – Marchamalo, Spain | ||||||
| AFB bacterin vs. Placebo | P. larvae | 1 | 0.26 | 0.13 | 0.01 | 0.501 |
| Control | 1 | 1.44 | 1.23 | 0.67 | - | |
General linear model with post-hoc contrast at both study sites (Site A—Graz, Austria, Site B—Marchamalo, Spain) and all challenges conducted (two challenges at Site A and one challenge at Site B). The contrast shows the queen treatments which are compared to each other (bacterin = AFB vaccination, Placebo = control vaccination), and Challenge treatment shows whether larvae were treated with the heterologous challenge (P. larvae) or placebo (Control). A p-value of 0.05 or less means a significant difference in mortality (SE = standard error).